ストックスクリーナーアプリを入手
16.53
2.10%
0.34
プレマーケット:
16.53
前日終値:
$16.19
開ける：
$16.07
24時間の取引高:
127.42K
Relative Volume:
0.68
時価総額：
$556.51M
収益：
$99.99M
当期純損益:
$-21.47M
株価収益率:
-25.06
EPS:
-0.6597
ネットキャッシュフロー:
$-11.34M
1週間 パフォーマンス:
+11.09%
1か月 パフォーマンス:
+27.15%
6か月 パフォーマンス:
+53.91%
1年 パフォーマンス:
+53.20%
1日の値動き範囲:
$16.00
$16.62
1週間の範囲:
$14.78
$16.62
52週間の値動き範囲:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.53 | 545.07M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications - Traders Union
NeuroPace Inc reports 77 percent drop in GTCs with NAUTILUS trial data - Traders Union
NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting - Traders Union
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE - Traders Union
Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside - DirectorsTalk Interviews
Here's why you should add NeuroPace stock to your portfolio now - MSN
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
Day Trade: Is NeuroPace Inc a stock for growth or value investorsMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Understanding Momentum Shifts in (NPCE) - Stock Traders Daily
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference - Investing News Network
Forecast Cut: Will NeuroPace Inc stock benefit from M AMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug EndMonth: Should I hold or sell NeuroPace Inc nowWeekly Risk Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Quarterly Recap: Whats the analyst consensus on NeuroPace IncM&A Rumor & Weekly High Return Stock Forecasts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
NeuroPace, Inc. (NPCE) stock price, news, quote and history - Yahoo Finance UK
NeuroPace Earnings Call Highlights Growth And AI Push - The Globe and Mail
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time - Bitget
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Zacks Investment Research
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High? - sharewise.com
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace Inc urges epilepsy patients to evaluate RNS System through online quiz - Traders Union
Avoiding Lag: Real-Time Signals in (NPCE) Movement - Stock Traders Daily
Global Neuromodulation Closed-Loop Brain-Computer Interfaces Market Set for 16.4% CAGR Surge Through 2036, Led by the United States, India & China; Key Players Medtronic, NeuroPace, Synchron Drive Algorithm-Centric Innovation - Morningstar
NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan
Aug Selloffs: What makes NeuroPace Inc stock attractive todayMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn
Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan
NeuroPace director granted 865 shares at $13 | NPCE Insider Trading - Stock Titan
NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan
NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
Discipline and Rules-Based Execution in NPCE Response - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
Wells Fargo Upgrades NeuroPace(NPCE.US) to Buy Rating, Raises Target Price to $19 - Moomoo
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NPCE SEC FilingsNeuropace Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.72%
大文字化:
|
ボリューム (24 時間):